



PATENT
Atty. Docket No. 33227-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David Bryant Batt et al.

Serial No: 10/560,352 Group Art Unit: 1624

Filed: May 12, 2006 Examiner: Deepak R. Rao

For: 2-AMINOPYRIMIDINE DERIVATIVES AS RAF KINASE INHIBITORS

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Restriction Requirement set forth in the Office Action dated December 16, 2008, Applicants hereby elect, with traverse, Group 1 (Claims 1-32). Applicants expressly reserve the right to file divisional applications or other appropriate measures deemed necessary to protect the inventions in the remaining, unelected claims.

The Commissioner is hereby authorized to charge any fees in connection with this Response to Deposit Account No. 50-4409.

Respectfully submitted,

By: Vinit Kathardekar
Vinit Kathardekar
Attorney for Applicants
Reg. No. 39,461

April 21, 2009

NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Intellectual Property – X-100B
P.O. Box 8097
Emeryville, California 94662-8097
(510) 923-3949
(510) 655-3542 (fax)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Mail Stop _____, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 22 day of April, 2009.

By David Bryant